Key Takeaways
- Board oversight should focus on assumptions, capabilities, investment, leadership, risk and progress—not every launch tactic.
- Ask who the real addressable patient is, who controls adoption and what could prevent access.
- Leadership should be able to name the five greatest launch risks immediately.
- Readiness must translate into measurable milestones the board can challenge before launch.
Boards do not need to manage the launch. They do need enough commercial visibility to understand whether management has identified the major risks.
The following questions can help. They pair well with a commercial readiness checklist and board commercial advisory.
Twelve Questions
1. Who Is the Real Addressable Patient?
Not theoretical prevalence. Who is diagnosed, eligible and realistically reachable?
2. Where Are Those Patients?
Are they distributed broadly or concentrated within specialist centers?
3. Who Controls the Treatment Decision?
Prescriber? Academic center? Payer? Institution? Referral specialist?
4. What Must Change for Physicians to Adopt the Product?
Clinical evidence alone does not automatically change behavior.
5. What Could Prevent Patient Access?
Understand reimbursement, distribution and administrative barriers.
6. What Evidence Is Missing?
Are important commercial evidence gaps being identified early enough?
7. What Does the Competitive Market Look Like at Launch?
Today’s landscape may not resemble the launch environment.
8. What Capabilities Must Be Built?
Understand organizational requirements beyond sales and marketing.
9. Are We Hiring at the Right Time?
Too early creates cost. Too late creates execution risk.
10. Are Functions Aligned?
Does Medical Affairs describe the market differently from Commercial? Does Market Access operate from different assumptions?
11. What Are the Five Greatest Launch Risks?
Leadership should be able to answer this immediately.
12. How Will We Know We Are Ready?
Readiness must translate into measurable milestones—see launch readiness assessment.
Board Oversight Without Micromanagement
Effective board oversight is not about reviewing every launch tactic. It is about understanding assumptions, capabilities, investment, leadership, risk and progress.
Commercial readiness should be visible enough that the board can challenge the strategy before launch rather than explain the outcome afterward.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
